RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in bone marrow and blood samples from older patients with acute myeloid leukemia treated with cytarabine-based therapy.
OBJECTIVES: Primary * To validate a pre-specified proteomic classifier to predict the likelihood of complete response (CR) to cytarabine-based induction chemotherapy in older patients with non-M3 acute myeloid leukemia. Secondary * To identify signaling nodes associated with risk of relapse among these patients who achieve a CR to induction chemotherapy. OUTLINE: This is a multicenter study. Previously collected bone marrow and peripheral blood samples are analyzed to validate the association of a pre-specified proteomic signature with clinical response via flow cytometry.
Study Type
OBSERVATIONAL
Enrollment
200
Proportion of patients achieving a complete response to induction chemotherapy
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.